Integrated Annual Report

Overview

The report describes Biocon's FY24 consolidated revenue growth to ₹156,212 million, completion of the acquired Viatris biosimilars integration across 120+ countries, and continued expansion of its global biosimilars business. It also highlights ESG progress, including achievement of Sustainability Linked Loan KPIs and improved sustainability ratings. The Group reported a workforce of 16,315 and 25% women representation in the Group workforce.

Document

Report type: Integrated Report
Class: Embedded
Scope: Full report
Fiscal year: 2024
Period: 1 April 2023 – 31 March 2024
Language: English
Pages
File size
Restatement: Disclosed

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Ratings

GRI level
CDP score

Materiality

Assessment
Basis

Assurance

Provider
Level
Standard
Scope
Statement included
Metrics assured

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services